1. Home
  2. RIGL vs IMMR Comparison

RIGL vs IMMR Comparison

Compare RIGL & IMMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • IMMR
  • Stock Information
  • Founded
  • RIGL 1996
  • IMMR 1993
  • Country
  • RIGL United States
  • IMMR United States
  • Employees
  • RIGL N/A
  • IMMR N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • IMMR Computer peripheral equipment
  • Sector
  • RIGL Health Care
  • IMMR Technology
  • Exchange
  • RIGL Nasdaq
  • IMMR Nasdaq
  • Market Cap
  • RIGL 247.1M
  • IMMR 271.9M
  • IPO Year
  • RIGL 2000
  • IMMR 1999
  • Fundamental
  • Price
  • RIGL $25.04
  • IMMR $8.66
  • Analyst Decision
  • RIGL Buy
  • IMMR Strong Buy
  • Analyst Count
  • RIGL 5
  • IMMR 1
  • Target Price
  • RIGL $31.30
  • IMMR $13.50
  • AVG Volume (30 Days)
  • RIGL 288.9K
  • IMMR 546.1K
  • Earning Date
  • RIGL 11-07-2024
  • IMMR 11-26-2024
  • Dividend Yield
  • RIGL N/A
  • IMMR 2.08%
  • EPS Growth
  • RIGL N/A
  • IMMR 57.07
  • EPS
  • RIGL 0.22
  • IMMR 2.04
  • Revenue
  • RIGL $157,374,000.00
  • IMMR $163,133,000.00
  • Revenue This Year
  • RIGL $38.26
  • IMMR $988.71
  • Revenue Next Year
  • RIGL $24.21
  • IMMR $88.38
  • P/E Ratio
  • RIGL $109.79
  • IMMR $4.24
  • Revenue Growth
  • RIGL 21.65
  • IMMR 338.21
  • 52 Week Low
  • RIGL $7.48
  • IMMR $6.33
  • 52 Week High
  • RIGL $29.82
  • IMMR $13.94
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.80
  • IMMR 51.92
  • Support Level
  • RIGL $22.33
  • IMMR $8.22
  • Resistance Level
  • RIGL $29.16
  • IMMR $8.69
  • Average True Range (ATR)
  • RIGL 2.30
  • IMMR 0.33
  • MACD
  • RIGL 0.41
  • IMMR 0.00
  • Stochastic Oscillator
  • RIGL 69.96
  • IMMR 36.97

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About IMMR Immersion Corporation

Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.

Share on Social Networks: